Bengaluru-based biotechnology startup CrisprBits has raised $3 million in a Pre-Series A round to accelerate its next stage of growth. The funding will enable the rollout of its PathCrisp molecular diagnostics platform and support expanded manufacturing for large-scale testing. The company is also preparing for international expansion and new applications in sustainability and bioengineering.
Funding round details
The round was led by Spectrum Impact, the family office of Rajendra Gogri, Chairman and Managing Director of Aarti Industries. Existing investors such as the Vijay Alreja Family Office of VJ Technologies Group and C-CAMP participated again, alongside new backing from members of the promoter family of HBL Engineering. The latest raise places the company’s valuation at approximately $12 million, signaling increased investor confidence in its commercial trajectory.
Technology and product portfolio
Founded by BITS Pilani alumni Vijay Chandru, Sunil Arora, Rajeev Kohli, Bharat Jobanputra, and Aditya Sarda, CrisprBits develops CRISPR-based platforms for diagnostics, genome engineering, and therapeutics. The startup operates a 7,300 square foot research and prototype facility in Bengaluru dedicated to advancing CRISPR technologies. Its portfolio includes PathCrisp for molecular diagnostics, EdiCrisp for gene editing and strain engineering, and CurieCrisp for rare disease-focused therapeutic development.
Commercialization and market expansion
A significant portion of the new capital will be used to commercialize PathCrisp and build manufacturing capacity for high-volume tests across human, food, and animal health. The company is currently creating diagnostic tests for sickle cell disease, typhoid, and antimicrobial resistance to address critical gaps in healthcare. Over the next six months, it plans to enter markets in Africa and Latin America while strengthening infrastructure and developing an AI-enabled strain engineering platform for sustainability and biofuels.
Strategic vision and leadership
CEO Vijay Chandru stated that CrisprBits has focused on securing patient capital that aligns with its mission to “rewrite biology and reimagine the planet.” He emphasized that the combination of scientific expertise in CRISPR and commercially driven leadership will fuel the company’s expansion. The new funding, he said, provides the momentum needed to move from research into large-scale real-world deployment.
The Pre-Series A investment marks a pivotal shift as CrisprBits transitions from technology development to global commercialization. With fresh capital, a defined product roadmap, and expanding production capabilities, the company is positioned to compete in diagnostics and CRISPR-driven sustainability solutions. Its success in new markets and progress in AI-powered strain engineering will be key measures of its impact in the year ahead.